Thalassemia is an incurable genetic disorder that disrupts hemoglobin production, necessitating continuous blood transfusions for affected individuals. The only potential cure is a bone marrow transplant, also known as a haematopoietic stem cell transplant (HSCT). Dr. Abhay Bhave, a Senior Consultant at S.L. Raheja Hospital in Mahim, explains that this procedure involves replacing faulty stem cells with healthy ones from a donor to restore normal blood cell production. Optimal outcomes are achieved when transplants occur early in life, ideally with sibling donors, as they provide the best match. Recent advancements in HSCT have improved safety and efficacy, with cure rates exceeding 85% in selected children. However, the procedure is complex and can lead to complications such as graft-versus-host disease (GVHD) and increased infection risk due to immunosuppression. Despite these challenges, ongoing developments in medical technology have made the process safer. Additionally, raising awareness about thalassemia prevention, including genetic counseling and carrier testing, is essential to combat the disease's prevalence. With proper medical support and early intervention, many patients can achieve full recovery.